文献速递淋巴瘤

初诊T淋巴母细胞淋巴瘤患者成功结局:儿童肿瘤协作组AALL0434研究结果

Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
PubMed 文献 · J Clin Oncol · 2020-06-17

儿童肿瘤协作组AALL0434方案评估以Capizzi方案甲氨蝶呤/培门冬酶为基础的多药化疗在初诊儿童T淋巴母细胞淋巴瘤中的安全性与疗效,并获取奈拉滨用于高危患者的初步数据。共纳入299例1-31岁患者,4年无事件生存率和总生存率分别为84.7%±2.3%和89.0%±2.0%,高危与标危组无病生存无差异。

要点

  • 299例1-31岁初诊T淋巴母细胞淋巴瘤患者接受ABFM C-MTX方案,4年EFS为84.7%±2.3%、OS为89.0%±2.0%。
  • 高危与标准风险组无病生存无差异(P=.29),奈拉滨未显示对高危患者的优势(P=.55)。
  • 未行预防性颅脑放疗,仅4例发生中枢神经系统复发。

核心结论

  • COG AALL0434在迄今规模最大的初诊T淋巴母细胞淋巴瘤试验之一中取得优异结局,ABFM方案联合C-MTX在不进行颅脑放疗的情况下提供优异的无事件生存率和总生存率。

研究设计与样本

  • 儿童肿瘤协作组(COG)AALL0434方案纳入299例年龄1-31岁的初诊T淋巴母细胞淋巴瘤患者。
  • 高危患者定义为诊断时骨髓可检测到≥1%微小病灶(MDD)或既往接受过类固醇治疗。
  • 诱导失败定义为4周诱导结束时未达到部分缓解(PR)。
  • 所有患者接受增强型柏林-法兰克福-明斯特(ABFM)C-MTX方案。
  • 高危患者随机分配接受或不接受6个5天疗程的奈拉滨加入ABFM方案。

主要发现

  • 诱导结束时,98.8%可评估患者至少达到部分缓解。
  • 4年无事件生存率(EFS)为84.7%±2.3%,总生存率(OS)为89.0%±2.0%。
  • 自诱导结束起的4年无病生存率(DFS)为85.9%±2.6%。
  • 高危与标准风险组之间无病生存无差异(P=.29),不同治疗方案之间亦无差异(P=.55)。
  • 疾病分期、肿瘤反应及诊断时MDD未显示导致EFS差异的阈值,奈拉滨未显示对高危患者的优势,仅4例发生中枢神经系统复发。

关键数值与推荐

  • 高危定义:诊断时骨髓≥1%MDD或既往类固醇治疗。
  • 诱导失败定义:4周诱导结束时未达到PR。
  • 中枢神经系统3级疾病(脑脊液白细胞≥5/μL伴原始细胞,或脑神经麻痹、脑/眼受累或下丘脑综合征)患者不符合入组条件。
  • 未行预防性颅脑放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Children's Oncology Group (COG) protocol AALL0434 evaluated the safety and efficacy of multi-agent chemotherapy with Capizzi-based methotrexate/pegaspargase (C-MTX) in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL) and gained preliminary data using nelarabine in high-risk patients. PATIENTS AND METHODS: The trial enrolled 299 patients, age 1-31 years. High-risk (HR) patients had ≥ 1% minimal detectable disease (MDD) in the bone marrow at diagnosis or received prior steroid treatment. Induction failure was defined as failure to achieve a partial response (PR) by the end of the 4-week induction. All patients received the augmented Berlin-Frankfurt-Muenster (ABFM) C-MTX regimen. HR patients were randomly assigned to receive or not receive 6 5-day courses of nelarabine incorporated into ABFM. Patients with induction failure were nonrandomly assigned to ABFM C-MTX plus nelarabine. No patients received prophylactic cranial radiation; however, patients with CNS3 disease (CSF WBC ≥ 5/μL with blasts or cranial nerve palsies, brain/eye involvement, or hypothalamic syndrome) were ineligible. RESULTS: At end-induction, 98.8% of evaluable participants had at least a PR. The 4-year event-free survival (EFS) and overall survival (OS) were 84.7% ± 2.3% and 89.0% ± 2.0%. The 4-year disease-free survival (DFS) from end-induction was 85.9% ± 2.6%. There was no difference in DFS observed between the HR and standard-risk groups (P = .29) or by treatment regimen (P = .55). Disease stage, tumor response, and MDD at diagnosis did not demonstrate thresholds that resulted in differences in EFS. Nelarabine did not show an advantage for HR patients. CNS relapse occurred in only 4 patients. CONCLUSION: COG AALL0434 produced excellent outcomes in one of the largest trials ever conducted for patients with newly diagnosed T-LL. The COG ABFM regimen with C-MTX provided excellent EFS and OS without cranial radiation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hayashi RJ, Winter SS, Dunsmore KP, et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. J Clin Oncol. 2020. PMID: 32552472. doi:10.1200/JCO.20.00531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。